Table 2. Details of chemotherapy and radiation treatment delivered.
| Treatment | Arm Aa (n = 65) | Arm Bb (n = 71) | All patients (n = 136) |
|---|---|---|---|
| Chemoradiotherapy phase | |||
| Number of patients | 59 | 66 | 125 |
| Percentage (%) | 90.8 | 93 | 91.9 |
| Cycle numbers of paclitaxel/cisplatin | |||
| Range | 1–2 | 1–2 | 1–2 |
| Consolidation chemotherapy | |||
| Number of patients | - | 64 | 64 |
| Percentage (%) | - | 90.1 | 47.1 |
| Cycle numbers of paclitaxel/cisplatin for consolidation chemotherapy | |||
| Range | - | 2–4 | - |
| Radiation therapy | |||
| Number of patients | 65 | 71 | 136 |
| Percentage (%) | 100 | 100 | 100 |
| Duration of external beam radiotherapy (days) | |||
| Median | 39 | 38 | 39 |
| Range | 35–45 | 33–46 | 35–46 |
| Total external beam radiotherapy dose (Gy) | |||
| Median | 48 | 48 | 48 |
| Range | 46–50 | 46–50 | 46–50 |
a
Arm A consisted of paclitaxel plus cisplatin chemotherapy combined with radiotherapy.
b
Arm B consisted of paclitaxel plus cisplatin chemoradiotherapy followed by paclitaxel plus cisplatin consolidation chemotherapy.